Lortlatinib
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALK-positive Non-small-cell Lung Cancer
Conditions
ALK-positive Non-small-cell Lung Cancer
Trial Timeline
Aug 2, 2021 → Dec 9, 2021
NCT ID
NCT04979988About Lortlatinib
Lortlatinib is a pre-clinical stage product being developed by Pfizer for ALK-positive Non-small-cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04979988. Target conditions include ALK-positive Non-small-cell Lung Cancer.
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04979988 | Pre-clinical | Completed |
Competing Products
9 competing products in ALK-positive Non-small-cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crizotinib + Pembrolizumab | Merck | Phase 1 | 21 |
| Ceritinib (LDK378) + Nivolumab | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 27 |
| Ceritinib | Novartis | Phase 2 | 35 |
| ceritinib + warfarin + midazolam | Novartis | Phase 1 | 29 |
| PF-02341066 + Rifampin + Itraconazole | Pfizer | Phase 1 | 29 |
| Lorlatinib | Pfizer | Phase 2 | 31 |
| crizotinib + alectinib + brigatinib + ceritinib + lorlatinib | Pfizer | Pre-clinical | 26 |
| PF-06463922 + Crizotinib | Pfizer | Phase 1/2 | 32 |